Arcus Biosciences, Inc. - Common Stock (RCUS)
CUSIP: 03969F109
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 122,470,452
- Total 13F shares
- 97,195,653
- Share change
- +13,164,736
- Total reported value
- $762,981,433
- Put/Call ratio
- 101%
- Price per share
- $7.85
- Number of holders
- 183
- Value change
- +$76,941,552
- Number of buys
- 126
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 03969F109?
CUSIP 03969F109 identifies RCUS - Arcus Biosciences, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03969F109:
Top shareholders of RCUS - Arcus Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13F
3/4/5
|
Company · 10%+ Owner |
25%
|
30,061,124
|
$447,610,136 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
7.9%
|
9,694,262
|
$144,347,559 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.4%
|
5,389,216
|
$80,245,427 | — | 31 Dec 2024 | |
| FMR LLC |
13F
|
Company |
3.3%
|
4,052,521
|
$60,342,038 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
2.9%
|
3,523,937
|
$52,471,422 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.4%
|
2,993,729
|
$44,576,625 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.6%
|
1,996,279
|
$29,724,594 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.4%
|
1,702,302
|
$25,348,057 | — | 31 Dec 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
1.3%
|
1,612,077
|
$24,003,827 | — | 31 Dec 2024 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.3%
|
1,602,200
|
$23,856,758 | — | 31 Dec 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
1.3%
|
1,547,591
|
$23,043,623 | — | 31 Dec 2024 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.2%
|
1,521,784
|
$22,659,000 | — | 31 Dec 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1%
|
1,273,789
|
$18,966,718 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.99%
|
1,209,613
|
$18,016,140 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.75%
|
924,369
|
$13,763,854 | — | 31 Dec 2024 | |
| Decheng Capital LLC |
13F
|
Company |
0.66%
|
808,789
|
$12,042,868 | — | 31 Dec 2024 | |
| BRAIDWELL LP |
13F
|
Company |
0.65%
|
802,100
|
$11,943,269 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.47%
|
579,623
|
$8,630,586 | — | 31 Dec 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.47%
|
576,156
|
$8,578,963 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.45%
|
549,914
|
$8,188,220 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.43%
|
532,099
|
$7,922,955 | — | 31 Dec 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.38%
|
465,304
|
$6,928,377 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.36%
|
443,453
|
$6,603,015 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.36%
|
443,000
|
$6,596,270 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.31%
|
381,615
|
$5,682,248 | — | 31 Dec 2024 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.31%
|
379,100
|
$5,645,000 | — | 31 Dec 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.31%
|
378,363
|
$5,633,825 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.29%
|
360,594
|
$5,369,245 | — | 31 Dec 2024 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.29%
|
351,356
|
$5,231,691 | — | 31 Dec 2024 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.28%
|
346,093
|
$5,153,325 | — | 31 Dec 2024 | |
| Trexquant Investment LP |
13F
|
Company |
0.25%
|
300,548
|
$4,475,160 | — | 31 Dec 2024 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.22%
|
263,517
|
$3,923,769 | — | 31 Dec 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.21%
|
254,217
|
$3,785,291 | — | 31 Dec 2024 | |
| AXA S.A. |
13F
|
Company |
0.19%
|
231,902
|
$3,453,021 | — | 31 Dec 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.18%
|
225,167
|
$3,352,737 | — | 31 Dec 2024 | |
| NORDEA INVESTMENT MANAGEMENT AB |
13F
|
Company |
0.18%
|
218,930
|
$3,244,542 | — | 31 Dec 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.17%
|
203,987
|
$3,037,366 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.17%
|
202,500
|
$3,015,225 | — | 31 Dec 2024 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.15%
|
180,122
|
$2,682,000 | — | 31 Dec 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.14%
|
170,000
|
$2,531,300 | — | 31 Dec 2024 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.14%
|
165,965
|
$2,471,219 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.13%
|
160,145
|
$2,384,559 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.13%
|
159,264
|
$2,371,413 | — | 31 Dec 2024 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
0.13%
|
153,783
|
$2,289,829 | — | 31 Dec 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0.12%
|
149,207
|
$2,221,692 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.12%
|
146,686
|
$2,184,155 | — | 31 Dec 2024 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.11%
|
135,030
|
$2,010,597 | — | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.11%
|
134,997
|
$2,010,105 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.11%
|
131,859
|
$1,963,381 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.11%
|
131,064
|
$1,951,543 | — | 31 Dec 2024 |
Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) as of Q1 2025
As of 31 Mar 2025,
Arcus Biosciences, Inc. - Common Stock (RCUS) was held by
183 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
97,195,653 shares.
The largest 10 holders included
GILEAD SCIENCES, INC., BlackRock, Inc., VANGUARD GROUP INC, Woodline Partners LP, FMR LLC, STATE STREET CORP, Point72 Asset Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, and BNP PARIBAS ASSET MANAGEMENT Holding S.A..
This page lists
183
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
185
Q1 2025 holders
183
Holder diff
-2
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.